Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy
Laura A. Sena, Hao Wang, Su J. Lim ScM, Irina Rifkind, Nduku Ngomba, John T. Isaacs, Jun Luo, Caroline F. Pratz, Victoria J. Sinibaldi, Michael A. Carducci, Channing J. Paller, Mario A. Eisenberger, Mark C. Markowski, Emmanuel S. Antonarakis, Samuel R. Denmeade
Topics & Concepts
EnzalutamideMedicineProstate cancerTestosterone (patch)Internal medicineAndrogen deprivation therapyAndrogenAntiandrogenOncologyHormonal therapyClinical endpointAndrogen receptorAbiraterone acetateUrologyEndocrinologyCancerHormoneClinical trialProstate Cancer Treatment and ResearchAdvanced Breast Cancer TherapiesHormonal and reproductive studies